August 2013 – The CenterWatch Monthly : Print
Will end-to-end outsourcing take hold?
Decisions for and against vertical integration are creating wider differences among CROs. Industry analysts and observers are closely watching the success of global CROs—including Covance and WuXi PharmaTech—that offer a broad range of services across the R&D spectrum, to see if other leading CROs will move toward expanding portfolios beyond their established clinical research services domain.
Medical device outsourcing poised to grow rapidly
More sponsors using larger, complex clinical trials to enhance product positioning. Medical device companies increasingly turn to CROs for clinical development work as they look for cost-effective and efficient ways to meet rising regulatory demands and pressures to expand into global markets...
Also in this issue:
- Buying options for patient recruitment services
- Avoiding monitor burnout during clinical trials
- Regulatory Update
- Month in Review
- FDA Actions
- Study Lead Opportunities
- New Drugs in the Pipeline